Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

Eupraxia Pharma reports positive data from RESOLVE phase 1b/2a trial of EP-104GI for treatment of eosinophilic esophagitis: Victoria, British Columbia Thursday, November 14, 2024, ...

Eosinophilic esophagitis (EoE) is a chronic esophageal ... Adults typically present with dysphagia and food impaction. No pathognomonic features have been identified for EoE and, therefore ...

Eosinophilic esophagitis (EoE) presents with a constellation of symptoms including feeding difficulties, abdominal pain, dysphagia, food sticking sensation and food impactions. While the ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...

23,24 In October 2021, tezepelumab was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA ...

Saint Alphonsus is trying to make a difference in the community. Screening and help with Esophageal health are just some of ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

The Latest These two diets have their fair share of followers, but they're aimed at people with differing goals. A dietitian shares safe and supportive weight loss strategies for larger kids.

Our gut microbiome, an ecosystem of ... A Safer Treatment Path for High-Risk Children to Overcome Food Allergies Feb. 28, 2024 — New research reveals a safe path to overcoming food allergies for ...